Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
37 studies found for:    Open Studies | "Hypoglycemic Agents"
Show Display Options
Rank Status Study
21 Recruiting Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Lixisenatide (AVE0010);   Drug: Oral anti-diabetic drugs
22 Recruiting Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
23 Recruiting Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: INSULIN GLARGINE (U300);   Drug: Insulin degludec;   Drug: GLP-1 receptor agonist;   Drug: Glimepiride;   Drug: Metformin
24 Recruiting A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: INSULIN GLARGINE (U300);   Drug: metformin;   Drug: sulfonylurea;   Drug: meglitinides;   Drug: thiazolidinediones;   Drug: alpha-glucosidase inhibitors;   Drug: GLP1 Receptor Agonist;   Drug: Dipeptidyl peptidase-IV (DPP-IV) inhibitors;   Drug: Sodium-glucose transport-2 (SGLT-2) inhibitors
25 Recruiting Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: INSULIN GLARGINE
26 Recruiting Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Behavioral: Active titration algorithm;   Behavioral: Usual titration algorithm
27 Recruiting Acute Liver Injury in Patients on Dapagliflozin
Condition: Acute Liver Injury
Intervention:
28 Recruiting A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: Dulaglutide;   Drug: Placebo
29 Recruiting Complications of UTI in Patients on Dapagliflozin
Condition: Severe Complications of Urinary Tract Infections
Intervention:
30 Recruiting ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon
Condition: Diabetes Mellitus Type 1
Interventions: Drug: ZP4207(dasiglucagon) glucagon analogue;   Drug: Glucagon (Native glucagon)
31 Recruiting The Hellenic Postprandial Lipemia Study (HPLS)
Conditions: Coronary Heart Disease;   Dyslipidemia
Intervention:
32 Recruiting Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)
Condition: Polycystic Ovary Syndrome (PCOS)
Interventions: Drug: DLBS3233;   Drug: Metformin XR;   Drug: Placebo caplet of Metformin XR;   Drug: Placebo capsule of DLBS3233
33 Recruiting Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)
Condition: Diabetes
Intervention: Device: Continuous Glucose Monitoring System
34 Recruiting Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects
Condition: Qt Interval, Variation in
Interventions: Drug: Placebo;   Drug: Imeglimin;   Drug: Moxifloxacin
35 Recruiting Metformin Use in Chronic Kidney Disease: The CKD-Met Study
Conditions: Type 2 Diabetes;   Chronic Kidney Disease
Intervention: Other: modalities of metformin prescription
36 Recruiting Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia
Conditions: Type 1 Diabetes Mellitus;   Nocturnal Hypoglycemia;   Recurrent Severe Hypoglycaemia
Interventions: Drug: Insulin aspart/glargine;   Drug: Insulin aspart/degludec
37 Recruiting Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol for oral suspension placebo proxy;   Drug: Welchol for oral suspension

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-37) Next Page   
Study has passed its completion date and status has not been verified in more than two years.